Frank Torti is the Vant Chair at Roivant Sciences, Chairman and Chief Executive Officer of Telavant, and Executive Chairman of Immunovant.
In his role at Roivant, Dr. Torti serves as Chairman, Executive Chairman, or CEO of the public and private biopharmaceutical companies (Vants) at Roivant and is responsible for those businesses. This group of companies has advanced over forty medicines into clinical development, produced positive phase three results in ten consecutive clinical trials, and generated over twelve billion dollars in value. In addition, companies created at Roivant have delivered six FDA approvals and have brought novel medicines in dermatology, oncology, immunology, men’s and women’s health, and rare disease to millions of patients.
During the course of his career, Dr. Torti has been Chairman of the Board of fifteen companies and served on more than thirty corporate boards. He has been involved in more than $22 billion in capital formation through fundraising, partnerships, and corporate acquisitions, and companies with which he has been involved have completed approximately twenty initial public offerings and M&A transactions.
Prior to joining Roivant, Dr. Torti was a partner at New Enterprise Associates (NEA), one of the largest venture capital firms in the world.
Dr. Torti received his BA with highest honors as a Morehead Scholar at the University of North Carolina, his MD from the University of North Carolina School of Medicine, and his MBA with distinction from Harvard Business School.
What is Frank Torti's net worth?
The estimated net worth of Frank Torti is at least $388.19 million as of February 23rd, 2026. Torti owns 13,736,547 shares of Roivant Sciences stock worth more than $388,194,818 as of February 24th. This net worth approximation does not reflect any other assets that Torti may own. Learn More about Frank Torti's net worth.
How do I contact Frank Torti?
Has Frank Torti been buying or selling shares of Roivant Sciences?
During the last ninety days, Frank Torti has sold $82,039,460.40 in shares of Roivant Sciences stock. Most recently, Frank Torti sold 587,390 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $27.51, for a transaction totalling $16,159,098.90. Following the completion of the sale, the insider now directly owns 13,736,547 shares of the company's stock, valued at $377,892,407.97. Learn More on Frank Torti's trading history.
Who are Roivant Sciences' active insiders?
Are insiders buying or selling shares of Roivant Sciences?
In the last year, Roivant Sciences insiders bought shares 2 times. They purchased a total of 16,669,981 shares worth more than $350,049,943.05. In the last year, insiders at the sold shares 54 times. They sold a total of 26,216,037 shares worth more than $508,898,353.56. The most recent insider tranaction occured on February, 23rd when insider Frank Torti sold 587,390 shares worth more than $16,159,098.90. Insiders at Roivant Sciences own 10.8% of the company.
Learn More about insider trades at Roivant Sciences. Information on this page was last updated on 2/23/2026.
